Joyvié Health Raises $1.04M in Pre-Seed Round to Launch Continence Underwear

Why It Matters

The capital enables Joyvié to address a massive, under‑served market—faecal incontinence affecting over 650 million people—while reducing caregiver burden and healthcare costs. Success could reshape standards for non‑invasive continence care and highlight the untapped potential of women‑focused health‑tech ventures.

Key Takeaways

• Joyvié raised €897k ($1.04M) for innovative continence underwear
• Product cuts stool‑to‑skin contact ~90% and change time ~70%
• Funding mix includes Innovate UK grant and several angel investors
• Faecal incontinence impacts 656 million globally, yet solutions are dated
• Women‑focused health‑tech receives only ~2% of VC capital

Pulse Analysis

The continence market has long relied on generic nappies that trap waste against vulnerable skin, leading to infections, dignity loss, and high caregiver workload. Joyvié Health’s redesign, born from a personal tragedy, uses a sealed pouch to capture stool immediately after excretion. Early testing shows a dramatic 90% reduction in skin exposure and a 70% faster change process, promising both clinical benefits and a more humane user experience. This innovation aligns with a broader shift toward patient‑centric medical devices that prioritize comfort, hygiene and environmental impact.

Joyvié’s €897,000 pre‑seed raise underscores growing investor appetite for niche health‑tech solutions, especially those tackling overlooked conditions. While the European health‑tech sector saw over €173 million in related funding this year, women‑focused ventures still capture a fraction—about 2% of total VC dollars—despite serving half the population. Lavender Ventures and SyndicateRoom’s backing signals confidence that Joyvié can capture a sizable slice of the global faecal incontinence market, a segment traditionally ignored by mainstream capital.

If pilot programmes confirm the product’s efficacy, Joyvié could deliver measurable cost savings for care facilities by reducing skin‑related complications and staff time per change. Moreover, the direct‑to‑consumer launch may empower individuals and families to manage incontinence at home, easing pressure on overstretched health systems. The company’s roadmap—clinical data, white papers, strategic partnerships—positions it to influence policy, set new care standards, and potentially attract follow‑on funding to scale internationally.

Deal Summary

UK‑based Joyvié Health announced the close of its pre‑Seed funding round, securing €897k ($1.04 million) from HERmesa Angels, SyndicateRoom, Lavender Ventures and individual angels. The capital will fund the launch of its continence underwear product, pilot programmes in care settings, and early hires. The round underscores growing investor interest in health‑tech solutions for incontinence care.